Downloads: 136

Files in This Item:
File Description SizeFormat 
s41598-019-46548-3.pdf1.18 MBAdobe PDFView/Open
Title: Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma
Authors: Goto, Megumi
Chamoto, Kenji  kyouindb  KAKEN_id
Higuchi, Keiko
Yamashita, Saya
Noda, Kenta
Iino, Takuya
Miura, Masahiro
Yamasaki, Toshinari  kyouindb  KAKEN_id
Ogawa, Osamu
Sonobe, Makoto
Date, Hiroshi
Hamanishi, Junzo  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-7750-0623 (unconfirmed)
Mandai, Masaki
Tanaka, Yoshimasa
Chikuma, Shunsuke
Hatae, Ryusuke
Muto, Manabu  kyouindb  KAKEN_id
Minamiguchi, Sachiko  kyouindb  KAKEN_id
Minato, Nagahiro
Honjo, Tasuku
Author's alias: 茶本, 健司
山﨑, 俊成
小川, 修
園部, 誠
伊達, 洋至
濵西, 潤三
万代, 昌紀
田中, 義正
竹馬, 俊介
波多江, 龍亮
武藤, 学
南口, 早智子
湊, 長博
本庶, 佑
Keywords: Biomarkers
Immune evasion
Tumour immunology
Issue Date: 12-Jul-2019
Publisher: Springer Nature
Journal title: Scientific Reports
Volume: 9
Thesis number: 10144
Abstract: Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients’ immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.
Rights: © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
URI: http://hdl.handle.net/2433/244073
DOI(Published Version): 10.1038/s41598-019-46548-3
PubMed ID: 31300681
Appears in Collections:学術雑誌掲載論文等

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.